Jim Tananbaum is the founder as well as CEO of Foresite Capital. This was in 2011 that he developed Foresite Capital as a private equity firm that was dedicated to healthcare. It specializes in identifying the emerging leaders in healthcare. The firm helps them to grow and become profitable. This is done by supplying them with necessary resources such as capital, networks, as well as relevant information.
He is a math and electrical engineering major from Yale. Jim Tananbaum received his M.D. as well as M.B.A. from the Harvard University. He did his M.S. from the Massachusetts Institute of Technology. He has always been passionate about combining hard sciences along with computer science and healthcare.
Jim Tananbaum has over 25 years of experience being a healthcare entrepreneur along with an investment strategist. During this time he was able to identify the key success factors that can help entrepreneurs and companies. All this is available in the science that is behind innovation along with the teams that are able to make it happen.
Foresite Capital tries to understand the future of healthcare and harness it accordingly. This is because innovative products and solutions in healthcare would require much more time as well as capital than what entrepreneurs and financiers realize. Foresite can play a critical role here for these emerging leaders. This is done by collecting as well as digesting all the published information that is available here about advances in healthcare. This helps to understand what is required in order to truly impact care. This would help to determine the investment prospects that are the most viable and have the highest probability score of success.
Foresite Capital has already invested in 77 healthcare companies (https://inc42.com/buzz/forbes-midas-top-100-investors-2017/). These are in fields such as biopharmaceuticals, besides medical services, as well as diagnostics along with genomic sequencing. A few of these investments include 10x Genomics, besides Intarcia Therapeutics, as well as Aerie Pharmaceuticals along with Aimmune Therapeutics.
Jim Tananbaum likes to spend his work day with other members of his team. Hence he spends a lot of time on calls or in meetings. He likes to discuss the updates on existing portfolio companies, besides any new company presentations.